

# CITATION REPORT

List of articles citing

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

DOI: 10.1016/j.tmaid.2020.101663

Travel Medicine and Infectious Disease, 2020, 34, 101663.

**Source:** <https://exaly.com/paper-pdf/77546226/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
551	Pharmacological Advances of Chloroquine and Hydroxychloroquine: From Antimalarials to Investigative Therapies in COVID-19. <b>2020</b> , 15, 1934578X2095364		1
550	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. <b>2020</b> , 20, 1-112		2
549	Methylene blue inhibits replication of SARS-CoV-2 in vitro. <b>2020</b> , 56, 106202		29
548	Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. <b>2020</b> , 45, 703-713		7
547	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 37, 101873	8.4	38
546	COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. <b>2020</b> , 59, 1423-1424		2
545	Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. <b>2020</b> , 28, 2040206620961712		12
544	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". <b>2020</b> , 14, 1673-1680		31
543	Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review. <b>2020</b> , 12, 1759720X20947296		2
542	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. <b>2020</b> , 216, 107672		31
541	The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review. <b>2020</b> , 98, 115176		37
540	Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. <b>2020</b> , 406, 115237		12
539	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <b>2020</b> , 11, 5214		104
538	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. <b>2020</b> , 2020, 4312519		16
537	Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend SF PH4 (dry). <b>2020</b> , 56, 106201		1
536	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <b>2020</b> , 383, 2030-2040		628
535	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of R3union Island. <b>2020</b> , 23, 1-3		7

534	Nullane salus extra ecclesiam. <b>2020</b> , 37, 100714		2
533	Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 37, 101826	8.4	2
532	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. <b>2021</b> , 73, e4073-e4081		150
531	Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. <b>2020</b> , 56, 106192		8
530	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <b>2020</b> , 11, 585888		7
529	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <b>2020</b> , 225, 152008		39
528	Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases. <b>2021</b> , 50, 402-404		4
527	Research Collaboration and Outcome Measures of Interventional Clinical Trial Protocols for COVID-19 in China. <b>2020</b> , 8, 554247		2
526	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. <b>2020</b> , 131, 110668		59
525	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. <b>2020</b> , 38, 100776		20
524	Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 38, 101881	8.4	3
523	Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. <b>2020</b> , 13, 1183-1190		5
522	COVID-19 in lung transplant patients: A case series. <b>2020</b> , 20, 3234-3238		20
521	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. <b>2020</b> , 56, 106056		18
520	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. <b>2020</b> , 59, 176-190		44
519	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <b>2020</b> , 56, 106101		52
518	Safety perspectives on presently considered drugs for the treatment of COVID-19. <b>2020</b> , 177, 4353-4374		9
517	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 1135-1149	6.1	17

516	Clinical Characteristics and In-Hospital Mortality for COVID-19 Across The Globe. <b>2020</b> , 9, 553-559	20
515	The dynamic treatment of SARS-CoV-2 disease. <b>2020</b> , 33, 572-579	1
514	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. <b>2020</b> , 9,	23
513	Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review. <b>2020</b> , Volume 8, 7-21	4
512	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. <b>2020</b> , 25,	2
511	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. <b>2020</b> , 29, 100645	34
510	Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1). <b>2020</b> , 173, 137-142	21
509	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. <b>2020</b> , 7, 581521	23
508	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. <b>2020</b> , 8,	4
507	Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020. <b>2020</b> , 56, 106219	28
506	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. <b>2020</b> , 173, 287-296	129
505	COVID-19: a review. <b>2020</b> , 5, e07-e07	
504	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. <b>2020</b> , 11, 559996	1
503	COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report. <b>2020</b> , 20, 845	2
502	Value of electrocardiography in coronavirus disease 2019 (COVID-19). <b>2020</b> , 62, 39-45	31
501	Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. <b>2020</b> , 16, 2992-3000	6
500	Role for antimalarials in the management of COVID-19. <b>2020</b> , 32, 449-457	5
499	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study From Five Academic Centers. <b>2020</b> , 1, 234-243	29

498	COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. <b>2020</b> , 37, 100738	49
497	Evaluation of Current Therapies for COVID-19 Treatment. <b>2020</b> , 8,	9
496	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <b>2020</b> , 50, e13358	2
495	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. <b>2020</b> , 21,	27
494	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <b>2020</b> , 59, 1195-1216	18
493	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. <b>2020</b> , 13, 945-956	2
492	"COVID-19: diagnosis, management and prognosis": a new topical collection of Internal and Emergency Medicine. <b>2020</b> , 15, 747-750	10
491	[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. <b>2020</b> , 46 Suppl 1, 20-27	0
490	Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. <b>2020</b> , 213, 182-187	32
489	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. <b>2020</b> , 56, 106129	7
488	Searching for COVID-19 treatments: First, do no harm. <b>2020</b> , 77, 1899-1905	2
487	Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. <b>2020</b> , 43, 765-772	36
486	Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey. <b>2020</b> , 170, 106062	21
485	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <b>2020</b> , 10,	4
484	SARS-CoV 2 (Covid-19) Heterogeneous Mortality Rates across Countries May Be Partly Explained by Life Expectancy, Calorie Intake, and Prevalence of Diabetes. <b>2020</b> , 48, 1-6	5
483	No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19. <b>2020</b> , 51, 1765-1769	4
482	Current Options in the Treatment of COVID-19: A Review. <b>2020</b> , 13, 1999-2010	5
481	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. <b>2020</b> , 7, 562142	11

480	Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. <b>2020</b> , 13, 878-888	22
479	QTc Interval Prolongation and Life-Threatening Arrhythmias During Hospitalization in Patients With Coronavirus Disease 2019 (COVID-19): Results From a Multicenter Prospective Registry. <b>2021</b> , 73, e4031-e4038	13
478	Current Understanding of COVID-19 Clinical Course and Investigational Treatments. <b>2020</b> , 7, 555301	13
477	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. <b>2020</b> , 161, 105250	21
476	A critical analysis and review of Lancet COVID-19 hydroxychloroquine study. <b>2020</b> , 8, 1809236	0
475	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <b>2020</b> , 11, 562264	5
474	COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. <b>2020</b> , 2020, 8822753	3
473	Clinical presentation and outcomes of hospitalized adults with COVID-19: A systematic review. <b>2020</b> , 76, 3235-3257	7
472	Observational study of azithromycin in hospitalized patients with COVID-19. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238681	14
471	Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. <b>2020</b> , 11, 2159	6
470	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. <b>2020</b> , 2, e689-e697	29
469	Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. <b>2020</b> , 46, 139	35
468	Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. <b>2020</b> , 41, 1377-1386	11
467	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. <b>2020</b> , 25, 1108-1122	20
466	Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. <b>2020</b> , 585, 584-587	198
465	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. <b>2020</b> , 10, 599-609	3
464	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. <b>2020</b> , 8, 937	10
463	SARS-CoV-2 and rhinovirus/enterovirus co-infection in a critically ill young adult patient in Colombia. <b>2020</b> , 40, 34-43	3

462	Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. <b>2020</b> , 35, 1346-1353	12
461	Navigating shifting waters: rapid response to change in the era of COVID-19. <b>2020</b> , 50, 786-790	1
460	Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19). <b>2020</b> , 43, 349-368	2
459	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. <b>2020</b> , 11, 1969	5
458	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <b>2020</b> , 54, 416-437	22
457	[COVID-19 infection-update]. <b>2020</b> , 25, 1-8	
456	Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an repurposing study. <b>2020</b> , 12, 1815-1828	51
455	Predictive Value of 5 Early Warning Scores for Critical COVID-19 Patients. <b>2020</b> , 1-8	18
454	Directly Acting Antivirals for COVID-19: Where Do We Stand?. <b>2020</b> , 11, 1857	10
453	Is there any potential management against COVID-19? A systematic review and meta-analysis. <b>2020</b> , 28, 765-777	9
452	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. <b>2020</b> , 11, 656	24
451	Pharmacological treatments of COVID-19. <b>2020</b> , 72, 1446-1478	16
450	A Narrative Review of Emerging Therapeutics for COVID-19. <b>2020</b> , 4, 745-758	5
449	Taming the Autophagy as a Strategy for Treating COVID-19. <b>2020</b> , 9,	29
448	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. <i>Scientific Reports</i> , <b>2020</b> , 10, 22139	4.9 41
447	Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives. <b>2020</b> , 11, 606097	4
446	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. <b>2020</b> , 33, 177-189	0
445	Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care. <b>2020</b> , 8, 2050312120974174	3

444	Recent progress in the repurposing of drugs/molecules for the management of COVID-19. <b>2021</b> , 19, 889-897		9
443	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. <b>2020</b> , 17,		23
442	Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option. <b>2020</b> , 8, 1247		2
441	In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. <b>2020</b> , 25,		42
440	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. <b>2020</b> , 27, 493-504		78
439	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 35, 101738	8.4	300
438	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). <b>2020</b> , 251, 228-248		473
437	Lack of efficacy of hydroxychloroquine in covid-19. <b>2020</b> , 369, m2018		10
436	Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?. <b>2020</b> , 8, 185		7
435	COVID-19: An Update About the Discovery Clinical Trial. <i>Pharmaceuticals</i> , <b>2020</b> , 13,	5.2	8
434	Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?. <b>2020</b> , 60, 808-814		13
433	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 35, 101735	8.4	71
432	Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <b>2020</b> , 55, 106007		18
431	SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review. <b>2020</b> , 95, 1750-1765		92
430	Hydroxychloroquine and azithromycin as a treatment of COVID-19. <b>2020</b> , 15, 841-843		6
429	Tocilizumab administration in a refractory case of COVID-19. <b>2020</b> , 56, 106043		11
428	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. <b>2020</b> , 158, 104904		72
427	"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.". <b>2020</b> , 14, 589-596		78



426	Current evidence for directed and supportive investigational therapies against COVID-19. <b>2020</b> , 26,	0
425	Immunology of COVID-19: Current State of the Science. <b>2020</b> , 52, 910-941	962
424	A review of potential treatments to date in COVID-19 patients according to the stage of the disease. <b>2020</b> , 68, 93-104	13
423	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <b>2020</b> , 79, 859-866	575
422	Potential specific therapies in COVID-19. <b>2020</b> , 14, 1753466620926853	13
421	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). <b>2020</b> , 40, 591-601	55
420	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. <b>2020</b> , 16, 2260-2266	40
419	Possible therapeutic agents for COVID-19: a comprehensive review. <b>2020</b> , 18, 1005-1020	13
418	Utility and risk of dermatologic medications during the COVID-19 pandemic. <b>2020</b> , 33, e13833	2
417	COVID-19: What you need to know. <b>2020</b> , 20, 100756	7
416	Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 36, 101788	8.4 7
415	A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). <b>2020</b> , 40, 101214	58
414	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. <b>2020</b> , 286, 198070	75
413	Statistical Explorations and Univariate Timeseries Analysis on COVID-19 Datasets to Understand the Trend of Disease Spreading and Death. <b>2020</b> , 20,	37
412	Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?. <b>2020</b> , 39, 2461-2465	19
411	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. <b>2020</b> , 155, 23-25	0
410	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. <b>2020</b> , 132, 604-613	19
409	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. <b>2020</b> , 33, e13829	3

408	Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID-19 Clinical Trials. <b>2020</b> , 9, 435-443	2
407	SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. <b>2020</b> , 135, 242-250	53
406	Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. <b>2020</b> , 38, 100710	6
405	Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?. <b>2020</b> , 10, 010377	9
404	Predicting human microbe-drug associations via graph convolutional network with conditional random field. <b>2020</b> , 36, 4918-4927	31
403	Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. <b>2020</b> , 74, e13600	21
402	Lessons from SARS-CoV-2 Pandemic: Evolution, Disease Dynamics and Future. <b>2020</b> , 9,	7
401	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <b>2020</b> , 97, 396-403	330
400	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. <b>2020</b> , 6, 1028-1031	5
399	Hydroxychloroquine and COVID-19 - A narrative review. <b>2020</b> , 67, S147-S154	5
398	Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. <b>2020</b> , 18, 1119-1133	16
397	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. <b>2020</b> , 9, 1789284	3
396	Progress in the Research and Development of Anti-COVID-19 Drugs. <b>2020</b> , 8, 365	9
395	COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not. <b>2020</b> , 1298, 167-176	5
394	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 36, 101791	8.4 162
393	Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?. <b>2020</b> , 21, 64-65	6
392	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <b>2020</b> , 40, 1353-1360	19
391	Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. <b>2020</b> , 25, 1786-1792	4

390	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <b>2020</b> , 16, 659-666	40
389	BET 2: Hydroxychloroquine in the treatment of COVID-19. <b>2020</b> , 37, 451-453	
388	Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19. <b>2020</b> , 130, 162-163	3
387	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. <b>2020</b> , 56, 106078	29
386	Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis". <b>2020</b> , 83, e75-e76	
385	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). <b>2020</b> , 95, 1454-1466	57
384	Rethinking the role of hydroxychloroquine in the treatment of COVID-19. <b>2020</b> , 34, 6027-6037	82
383	QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine. <b>2020</b> , 50, e13258	11
382	Antiviral treatment of COVID-19. <b>2020</b> , 50, 611-619	144
381	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <b>2020</b> ,	11
380	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. <b>2020</b> , 155, 23-25	3
379	Incidence of coronavirus disease (COVID-19) and countries affected by malarial infections. <i>Travel Medicine and Infectious Disease</i> , <b>2020</b> , 37, 101693	8.4 7
378	Covid-19 pandemic by the "real-time" monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies. <b>2020</b> , 11, 1-6	29
377	COVID-19: Immunology and treatment options. <b>2020</b> , 215, 108448	321
376	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. <b>2020</b> ,	432
375	A novel plan to deal with SARS-CoV-2 and COVID-19 disease. <b>2020</b> , 92, 1394-1395	5
374	COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. <b>2020</b> , 123, 120-126	93
373	Chloroquine paradox may cause more damage than help fight COVID-19. <b>2020</b> , 22, 154-156	14

372	Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. <b>2020</b> , 92, 776-785		127
371	Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 201-211	6.1	100
370	Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. <b>2020</b> , 8, 539-541		82
369	Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review. <b>2020</b> , 41, 1108-1110		9
368	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <b>2020</b> , 7, ofaa130		122
367	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <b>2020</b> , 79, 734-736		32
366	Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 253-263	6.1	75
365	When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19. <b>2021</b> , 17, 1954-1963		80
364	COVID-19 and antimicrobial stewardship: What is the interplay?. <b>2021</b> , 42, 378-379		17
363	Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev. <b>2021</b> , 80, e20		2
362	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. <b>2021</b> , 22, 1232-1238		3
361	Molecular detection of microorganisms in lice collected from farm animals in Northeastern Algeria. <b>2021</b> , 74, 101569		2
360	An overview on the use of antivirals for the treatment of patients with COVID19 disease. <b>2021</b> , 30, 45-59		1
359	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. <b>2021</b> , 890, 173717		14
358	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <b>2020</b> ,		26
357	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a 'real-life' patient cohort. <b>2021</b> , 133, 284-291		22
356	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <b>2021</b> , 73, 36-47		34
355	Lung Ultrasound in COVID-19 A Role Beyond the Acute Phase?. <b>2021</b> , 40, 503-511		6

354	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. <b>2021</b> , 93, 775-785	11
353	COVID-19: Between Past and Present. <b>2021</b> , 34, 145-157	2
352	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. <b>2021</b> , 538, 156-162	4
351	Operational Recommendations for Scarce Resource Allocation in a Public Health Crisis. <b>2021</b> , 159, 1076-1083	7
350	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. <b>2021</b> , 46, 17-27	14
349	Does IHU-Mediterran� Infection influence Gilead Sciences' stock price?. <b>2021</b> , 39, 100711	1
348	Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. <b>2021</b> , 21, 36-43	6
347	Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. <b>2021</b> , 51, e13428	12
346	Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. <b>2021</b> , 75, e13868	23
345	Interferon-inducer antivirals: Potential candidates to combat COVID-19. <b>2021</b> , 91, 107245	17
344	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <b>2021</b> , 41, 1375-1426	11
343	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <b>2021</b> , 133, 111008	14
342	Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. <b>2021</b> , 54, e12953	8
341	Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France. <b>2021</b> , 40, 361-371	18
340	What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review. <b>2021</b> , 16, 806-816	6
339	Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity. <b>2021</b> , 64, 132-143	73
338	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. <b>2021</b> , 40, 41-46	14
337	COVID-19 outpatient management: Shorter time to recovery in Healthcare workers according to an electronic daily symptoms assessment. <b>2021</b> , 51, 71-76	0

336	Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. <i>Saudi Pharmaceutical Journal</i> , <b>2021</b> , 29, 1-11	4.4	69
335	Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). <b>2021</b> , 4, 1-13		10
334	Biocatalytic routes to anti-viral agents and their synthetic intermediates. <b>2021</b> , 50, 1968-2009		13
333	Emerging treatment strategies for COVID-19 infection. <b>2021</b> , 21, 167-179		81
332	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. <b>2021</b> , 54, 27-36		8
331	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <b>2021</b> , 53, 117-134		26
330	Community use of antibiotics during the COVID-19 lockdown. <b>2021</b> , 53, 142-144		8
329	Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. <b>2021</b> , 93, 1265-1275		8
328	Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. <b>2021</b> , 268, 1580-1591		19
327	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. <b>2021</b> , 87, 845-857		3
326	Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to. <b>2021</b> , 25, 625-659		27
325	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <b>2021</b> , 59, 12-23		24
324	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. <b>2021</b> , 394, 775-782		10
323	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. <b>2021</b> , 51, 127-138		4
322	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <b>2021</b> , 10, 34-48		37
321	Azithromycin in the treatment of COVID-19: a review. <b>2021</b> , 19, 147-163		71
320	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. <b>2021</b> , 25, 13-22		5
319	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. <b>2021</b> , 41, 5-28		43

318	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <b>2021</b> , 41, 257-273	0
317	Shedding light on therapeutics in alopecia and their relevance to COVID-19. <b>2021</b> , 39, 76-83	3
316	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. <b>2021</b> , 379, 4	8
315	Utility of early warning scores to predict mortality in COVID-19 patients: A retrospective observational study. <b>2021</b> , 11, 161-166	0
314	Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. <b>2021</b> , 12, 6	7
313	Therapeutic options for COVID-19: a quick review. <b>2021</b> , 33, 67-84	4
312	Azithromycin Plus Zinc Sulfate Rapidly and Synergistically Suppresses IBβ-Mediated In Vitro Human Airway Cell ACE2 Expression for SARS-CoV-2 Entry.	2
311	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. <b>2021</b> , 3, 192-197	0
310	Hydroxychloroquine and SARS-CoV-2 (COVID-19): An Old Problem and New Considerations in Ophthalmology. <b>2021</b> , 14, 78-81	
309	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. <b>2021</b> , 16, 558-570	2
308	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. <b>2021</b> , 25, 441-452	2
307	Hydroxychloroquine: A review of its safety and efficacy in COVID-19. <b>2021</b> , 10, 1124-1133	1
306	Human Viruses: Infection, Prevention and Potential Target(s) for Therapy   A Comprehensive Review. <b>2021</b> , 3-54	
305	A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020. <b>2021</b> , 18,	18
304	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. <b>2021</b> , 10, 2126-2139	1
303	The eye as the discrete but defensible portal of coronavirus infection. <b>2021</b> , 19, 176-182	32
302	Environmental Challenges and the Impact of COVID-19 on Healthcare Sector: The Adoption of Intelligent Solutions. <b>2021</b> , 41-53	
301	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. <b>2021</b> , 28,	11

300	Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. <b>2021</b> , 5, rkaa081	20
299	Molecular docking analysis of azithromycin and hydroxychloroquine with spike surface glycoprotein of SARS-CoV-2. <b>2021</b> , 17, 11-22	1
298	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <b>2021</b> , 93, 2694-2704	9
297	Therapeutic Development in COVID-19. <b>2021</b> , 1318, 435-448	1
296	Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data. <b>2021</b> , 51,	9
295	Therapeutic Strategies in the Management of COVID-19. <b>2020</b> , 7, 636738	8
294	Methodological quality of COVID-19 clinical research. <b>2021</b> , 12, 943	30
293	Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19. <b>2021</b> , 10,	10
292	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <b>2020</b> , 11, 583914	4
291	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. <b>2021</b> , 27, 694-707	1
290	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <b>2021</b> , 2, CD013587	57
289	Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. <b>2021</b> , 190, 1452-1456	9
288	Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. <b>2021</b> , 22, 62-66	2
287	Focus on azithromycin. <b>2021</b> , 2, 6-8	1
286	Risk Factors of Coronavirus Disease 2019-Related Mortality and Optimal Treatment Regimens: A Retrospective Study. <b>2021</b> , 27, e926751	1
285	The mass production of systematic reviews about COVID-19: An analysis of PROSPERO records. <b>2021</b> , 14, 56-64	6
284	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. <b>2021</b> , 54, 37-45	2
283	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. <b>2021</b> , 2021, 8821318	4



282	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. <b>2021</b> , 4, e1355	0
281	Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients. <b>2021</b> , 84, 233-241	17
280	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. <b>2021</b> , 12, 574425	13
279	Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients. <b>2020</b> , 11, 585021	2
278	Overview of COVID-19 patients treated in University Hospital Split, Croatia - specifics related to patients age. <b>2021</b> , 7,	
277	Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?. <b>2021</b> , 54, 997-1000	6
276	COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. <b>2021</b> , 8, 606755	2
275	The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications. <b>2021</b> ,	0
274	Reasoned therapeutic protocol in outpatients with COVID-19. <b>2021</b> , 40, 170-175	0
273	Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. <b>2021</b> , 10, 34-52	5
272	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. <b>2021</b> , 27, 281-290	8
271	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. <b>2021</b> , 35, 101658	2
270	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <b>2021</b> , 895, 173890	41
269	No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. <b>2021</b> , 104, 34-40	4
268	Demographic and clinical features associated with in-hospital mortality in Egyptian COVID-19 patients: A retrospective cohort study.	
267	Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. <b>2021</b> , 36, S253-S263	24
266	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <b>2021</b> , 397, 1063-1074	105
265	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. <b>2021</b> , 19, e3001128	25

264	Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?. <b>2021</b> , 12, 155	5
263	Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review. <b>2021</b> , 26, 1-11	3
262	Coronavirus disease 2019 (COVID-19) and QTc prolongation. <b>2021</b> , 21, 158	8
261	Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation. <b>2021</b> , 61, 2016-2025	2
260	4-Aminoquinoline compounds from the Spanish flu to COVID-19. <b>2021</b> , 135, 111138	3
259	Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia. <b>2021</b> , 57, 34-41	7
258	Present and future treatment strategies for coronavirus disease 2019. <b>2021</b> , 7, 84	7
257	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. <b>2021</b> , 19, 1331-1339	2
256	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. <b>2021</b> , 897190021997399	1
255	SARS-CoV-2 Therapy: Old Drugs as New Interventions. <b>2021</b> , 2, 142-150	1
254	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. <b>2021</b> , 64, 400-415	
253	Comment to Sands et al. - No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. <b>2021</b> , 105, 216	
252	Increased in-hospital mortality from COVID-19 in patients with schizophrenia. <b>2021</b> , 47, 89-95	16
251	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. <b>2021</b> , 9, E693-E702	7
250	Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. <b>2021</b> , 27, 1323-1329	
249	Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249036	3-7 1
248	Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020. <b>2021</b> , 26,	4
247	The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. <b>2021</b> , 39, 159-170	4

246	Repurposing of antibiotics for clinical management of COVID-19: a narrative review. <b>2021</b> , 20, 37		11
245	Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. <b>2021</b> , 11,		4
244	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. <b>2021</b> , 12, 675419		13
243	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. <b>2021</b> , 39, 430-445		1
242	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. <b>2021</b> , 23, 1124-1133		2
241	Correlation of the rise and fall in COVID-19 cases with the social isolation index and early outpatient treatment with hydroxychloroquine and chloroquine in the state of Santa Catarina, southern Brazil: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 41, 102005	8.4	1
240	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. <b>2021</b> , 13,		12
239	Review of a controversial treatment method in the fight against COVID-19 with the example of Algeria. <b>2021</b> , 45, 94		3
238	Therapeutic Agents Against COVID-19 with Clinical Evidence. <b>2021</b> , 27, 1608-1617		1
237	Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251340	3.7	27
236	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <b>2021</b> , 151, 112106		3
235	Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience. <b>2021</b> , 7,		
234	A study on the sentiments and psychology of twitter users during COVID-19 lockdown period. <b>2021</b> , 1-23		10
233	Electron Donor-Acceptor Capacity of Selected Pharmaceuticals against COVID-19. <b>2021</b> , 10,		3
232	Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. <b>2021</b> , 51, 912-920		9
231	Contagion Management at the Mediterranean Infection University Hospital Institute. <b>2021</b> , 10,		1
230	COVID-19 rhapsody: Rage towards advanced diagnostics and therapeutic strategy. <b>2021</b> , 11, 529-540		1
229	A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov. <b>2021</b> , 26,		8

228	Off Label Medication to Combat COVID-19: Review Results to Date. <b>2021</b> , 2, 496-506		
227	Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0252388	3.7	2
226	Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19. <b>2021</b> , 28, 3803-3824		7
225	The scientific community in COVID-19 global pandemic: A systematic update on recent progress and challenges. <b>2021</b> , 12, 222-234		
224	Pharmacological Effects of Selected Medicinal Plants and Vitamins Against COVID-19. <b>2021</b> , 7,		3
223	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <b>2021</b> , 76, 285-295		3
222	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <b>2021</b> , 19, 1219-1244		3
221	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <b>2021</b> , 11,		6
220	Clinical and epidemiological profile of Indian COVID-19 patients from Jaipur: a descriptive study. <b>2021</b> , 91,		0
219	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <b>2021</b> , 61, 3771-3788		6
218	The Effect of Azithromycin Plus Zinc Sulfate on ACE2 Expression through IB of Human Respiratory Cells in SARS-CoV-2: In Vitro Study. <b>2021</b> , 1, 263-275		0
217	Evaluation of the relationship between quantitative PCR results and cell culturing of SARS2-CoV with respect to symptoms onset and Viral load in a systematic review.		2
216	A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment. <b>2021</b> , 152, 568-582		10
215	COVID-19 in lung transplant recipients: A single-center experience. <b>2021</b> , 23, e13700		2
214	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. <b>2021</b> , 905, 174191		8
213	No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256035	3.7	
212	COVID-19: potential therapeutics for pediatric patients. <b>2021</b> , 73, 1520-1538		6
211	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. <b>2021</b> , 136, 55-63		6

210	Orbital inflammatory disease associated with COVID-19 infection. <b>2021</b> , 25, 232-234		12
209	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. <i>Travel Medicine and Infectious Disease</i> , <b>2021</b> , 43, 102135	8.4	4
208	Effects of cardiac toxicity of combination therapy with hydroxychloroquine and azithromycin in COVID-19 patients. <b>2021</b> , 14, 1668-1670		1
207	Experimental and clinical evaluation of mefloquine effectiveness against the infection caused by SARS-CoV-2. <b>2021</b> ,		
206	Therapeutic and protective potential of mesenchymal stem cells, pharmaceutical agents and current vaccines against covid-19. <b>2021</b> ,		1
205	Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. <b>2021</b> , 53, 318-334		10
204	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. <b>2021</b> , 18,		5
203	Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection. <b>2021</b> , 33, 1718-1722		1
202	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. <b>2021</b> , 10, 93-113		9
201	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. <b>2021</b> , 16, 281-308		21
200	The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. <i>PLoS ONE</i> , <b>2021</b> , 16, e0244778	3.7	25
199	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. <b>2021</b> , 21, 72		19
198	Pharmacotherapeutics of SARS-CoV-2 Infections. <b>2021</b> , 16, 12-37		3
197	Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center. <b>2021</b> , 33, 443-450		2
196	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. <b>2021</b> , 53, 166-219		11
195	Rationale for azithromycin in COVID-19: an overview of existing evidence. <b>2021</b> , 8,		23
194	Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19. <b>2021</b> , 379-416		7
193	Assessing the Impact of COVID-19 on Antimicrobial Stewardship Activities/Programs in the United Kingdom. <i>Antibiotics</i> , <b>2021</b> , 10,	4.9	17

192	Medications in COVID-19 patients: summarizing the current literature from an orthopaedic perspective. <b>2020</b> , 44, 1599-1603	17
191	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. <b>2020</b> , 15, 1501-1506	18
190	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <b>2020</b> , 53, 100721	44
189	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. <b>2020</b> , 14, 641-648	97
188	QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. <b>2020</b> , 17, 1472-1479	98
187	A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. <b>2020</b> , 56, 106028	62
186	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. <b>2020</b> , 88, 106942	5
185	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. <b>2020</b> , 38, 100770	10
184	[Covid-19: care protocols or research protocols?]. <b>2020</b> , 36, 521-523	2
183	Treatments in the COVID-19 pandemic: an update on clinical trials. <b>2020</b> , 25, 81-88	8
182	Natural history of COVID-19 and therapeutic options. <b>2020</b> , 16, 1159-1184	41
181	Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. <b>2020</b> , 99, e23720	14
180	COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice. <b>2020</b> , 6, e582	11
179	The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis.	17
178	Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19.	6
177	Current Understanding of COVID-19 Clinical Course and Investigational Treatments.	1
176	Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study.	21
175	Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis.	1

174	Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?.	7
173	Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France.	6
172	ProgNet: Covid-19 prognosis using recurrent and convolutional neural networks.	6
171	Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis.	12
170	Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions.	4
169	Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysis.	5
168	Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19.	5
167	In Silico design and characterization of multi-epitopes vaccine for SARS-CoV2 from its spike proteins.	4
166	COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. <b>2020</b> ,	5
165	A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications.	1
164	Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France.	17
163	Effect of hydroxychloroquine on SARS-CoV-2 viral load in patients with COVID-19.	1
162	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <b>2020</b> ,	16
161	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial).	31
160	A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19).	8
159	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.	82
158	Prevalence and clinical correlates of COVID-19 outbreak among health care workers in a tertiary level hospital in Delhi.	7
157	Determining the period of communicability of SARS-CoV-2: A rapid review of the literature.	3

156	Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real-world experience.		0
155	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study.		7
154	Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. <b>2020</b> , 10, 73		78
153	Myocarditis Associated With COVID-19. <b>2020</b> , 8, 498-502		9
152	COVID-19 gender susceptibility and outcomes: A systematic review. <i>PLoS ONE</i> , <b>2020</b> , 15, e0241827	3.7	19
151	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). <i>PLoS ONE</i> , <b>2020</b> , 15, e0242763	3.7	40
150	Therapeutic clinical trials to combat COVID-19 pandemic in India: analysis from trial registry. <b>2020</b> , 32, 267-278		1
149	Sustainable Post Covid19 Lockdown Strategy Through Evidence-Based Policy. 7,		5
148	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. <b>2020</b> , 27, e14-e25		4
147	COVID-19: etiology, clinical picture, treatment. <b>2020</b> , 10, 421-445		21
146	Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. <b>2020</b> , 25, 3517-3554		2
145	The COVID-19 Pandemic - A Global Public Health Crisis: A Brief Overview Regarding Pharmacological Interventions. <b>2020</b> , 20,		8
144	Novel coronavirus infection. <b>2020</b> , 98, 6-14		6
143	Ivermectin: Potential Role as Repurposed Drug for COVID-19. <b>2020</b> , 27, 154-158		7
142	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <b>2020</b> , 13, 4673-4695		20
141	Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point. <b>2020</b> , 6, e19199		26
140	No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. <b>2020</b> , 1, e19583		1
139	No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19 (Preprint).		2



138	Repurposing of drugs for Covid-19: a systematic review and meta-analysis. <b>2020</b> ,	2
137	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <b>2020</b> , 11, 597985	13
136	Should azithromycin be used to treat COVID-19? A rapid review. <b>2020</b> , 4,	21
135	In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. <b>2020</b> , 35, 782-787	36
134	Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?. <b>2020</b> , 12, 413-422	8
133	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <b>2020</b> , 49,	7
132	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. <b>2020</b> , 24, 1106-1113	1
131	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. <b>2020</b> , 11,	6
130	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. <b>2020</b> , 7, S110-S116	4
129	A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. <b>2020</b> , 7, S102-S106	1
128	COVID-19 compared to other epidemic coronavirus diseases and the flu. <b>2020</b> , 10, 1-13	4
127	Current status of COVID-19 treatment: An opinion review. <b>2020</b> , 9, 27-37	4
126	An overview of potential therapeutic agents to treat COVID-19. <b>2020</b> , 14, 318-327	4
125	Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. <b>2020</b> , 32, 166-196	22
124	Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. <b>2020</b> , 39, 488-499	3
123	Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. <b>2020</b> , 12, e8342	24
122	COVID-19 treatment in children: A systematic review and meta-analysis. <b>2021</b> , 10, 3292-3302	3
121	Evaluation of early antibiotic use in patients with non-severe COVID-19 without bacterial infection. <b>2021</b> , 106462	2

- 120 Personalized therapy: can it tame the COVID-19 monster?. **2021**, 18, 583-593 1
- 119 The Management of Elderly Patients with COVID Out of the Hospital: The Italian Experience. **2020**, 195-209
- 118 Managing a Hemodialysis Unit in Times of Pandemic to COVID-19. Experience of Edith Lucie Bongo Ondimba General Hospital. **2020**, 10, 223-226 1
- 117 Therapeutic Approach to Coronavirus Disease. **2020**, 67-97 0
- 116 Tratamiento para COVID-19. **2020**, 33, 42-51
- 115 Coronavirus Disease: New Humans Challenge and Known Approaches to Treatment. **2020**, 18-21 1
- 114 Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis. **2021**, 80, e9 1
- 113 Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19. 1
- 112 Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review.
- 111 Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials.
- 110 Repurposing of drugs for Covid-19: a systematic review and meta-analysis. 0
- 109 Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis. 0
- 108 Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments.
- 107 Meta-analysis. **2020**, 8, 73-87
- 106 Avaliação de tecnologias em saúde: tensões metodológicas durante a pandemia de Covid-19. **2020**, 34, 77-96 1
- 105 Virus-bacterial association of SARS-CoV-2 with mycoplasma as one of the possible causes of severe forms of COVID-19. **2020**, 143-151 1
- 104 Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020. 0
- 103 Drug repurposing in COVID-19: A review with past, present and future. **2021**, 12, 100121 9

102	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. <b>2020</b> , 01,	1
101	Markedly Lower Rates of Coronavirus Infection and Fatality in Malaria-Endemic Regions A Clue As to Treatment?.	
100	Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019. <b>2021</b> , 25, 184-190	1
99	Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent. <b>2020</b> , 11, 85-104	
98	Management of COVID-19: A brief overview of the various treatment strategies. <b>2020</b> , 3, 233	1
97	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. <b>2020</b> , 123, 74	
96	Maternal and Fetal Outcomes of COVID-19 Pregnant Women Followed Up at a Tertiary Care Unit: A Descriptive Study. <b>2020</b> , 10, 1482-1491	1
95	Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. <b>2020</b> , 61, 321-334	1
94	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.	1
93	Methodological Rigor in COVID-19 Clinical Research A Systematic Review and Case-Control Analysis.	1
92	FARMACOS ANTIMICROBIANOS E ANTIVIRAIS COM POTENCIAL USO TERAPÊUTICO PARA A COVID-19. <b>2020</b> , 32, 109-119	
91	COVID-19: challenges and opportunities. <b>2020</b> , 7, 141-143	
90	Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?. <b>2020</b> , 28, 246-247	1
89	The Comprehensive Appraisal of COVID-19: Its Clinical Panorama from Virology till Management and Beyond. <b>2020</b> , 1, 57-72	0
88	Farmacoterapia aplicada ^ COVID-19. 58-81	
87	ROMATOLOGIA PERSPECTIVAS EN COVID-19.	
86	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. <b>2020</b> ,	1
85	Therapeutic strategies against COVID-19. <b>2020</b> , 91, e2020038	2

84	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. <b>2021</b> , 13, 163-171		1
83	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. <b>2021</b> ,		1
82	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <b>2021</b> , 10, 1-32		0
81	[Citation misuse and its effects on public health]. <b>2021</b> , 37, 1035-1041		1
80	Demographic and Clinical Features Associated with in-Hospital Mortality in Egyptian COVID-19 Patients: A Retrospective Cohort Study. <b>2021</b> , 9, 1068-1075		0
79	Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study. <i>Therapeutics and Clinical Risk Management</i> , <b>2021</b> , 17, 1187-1198	2.9	0
78	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <b>2021</b> , 2021, 8554192		
77	A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial. <b>2021</b> , 22, 869		2
76	Suspect Screening of Wastewaters to Trace Anti-Covid-19 Drugs: Potential Adverse Effects on Aquatic Environment.		
75	The Importance of Glycosylation in COVID-19 Infection. <b>2021</b> , 1325, 239-264		3
74	Negative Nasopharyngeal SARS-CoV-2 PCR Conversion in Response to Different Therapeutic Interventions.. <b>2022</b> , 14, e21442		2
73	High-cited favorable studies for COVID-19 treatments ineffective in large trials.		
72	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1075	4.9	3
71	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein.. <b>2022</b> , 28, 37		
70	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).. <b>2022</b> , 8,		1
69	Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263437	3.7	4
68	An Overview of Quality of Research in COVID19. <b>2022</b> , 395-409		
67	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. <b>2022</b> , 58,		0

66	Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment.. <b>2022</b> , 824, 153756		1
65	Duration of viable SARS-CoV-2 shedding from respiratory tract in different human hosts and its impact on isolation discontinuation policies revision; a narrative review.. <b>2022</b> , 13, 100140		1
64	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence.. <b>2022</b> , e13763		1
63	Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.. <i>Pharmaceuticals</i> , <b>2022</b> , 15,	5.2	0
62	Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.. <b>2022</b> , 13, 844818		4
61	The ongoing Pharmacotherapy for ministration of Covid 19 disease: A Review. <b>2022</b> , 66-72		
60	Value and prognostic impact of a deep learning segmentation model of COVID-19 lung lesions on low-dose chest CT. <b>2022</b> , 1, 100003		0
59	A simple and efficient derivatization strategy combined with switchable solvent liquid-liquid microextraction-hydroxychloroquine methyl acetate-d based quadruple isotope dilution-gas chromatography-mass spectrometry for the determination of hydroxychloroquine sulfate in biological fluids.. <b>2022</b> , e9282		1
58	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. <b>2022</b> ,		1
57	Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study.. <i>Antibiotics</i> , <b>2022</b> , 11,	4.9	0
56	Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.. <b>2022</b> , 71, 126954		1
55	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. <b>2022</b> ,		0
54	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. <b>2021</b> , 13, 1850-1874		1
53	A critical analysis about the supposed role of azithromycin in the treatment of covid-19. <b>2021</b> , 11, 11-21		
52	The Significance of Coordinated Research Against SARS-CoV-2. <b>2022</b> , 698-713		
51	Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.. <i>Scientific Reports</i> , <b>2022</b> , 12, 4925	4.9	5
50	Epigenetic regulation of autophagy in coronavirus disease 2019 (COVID-19).. <i>Biochemistry and Biophysics Reports</i> , <b>2022</b> , 30, 101264	2.2	
49	Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19: Randomized, double blind, Placebo controlled trial		

48	Possible role of Kolaviron, a Garcinia kola bioflavonoid in inflammation associated COVID-19 infection. 2, 3		0
47	Data_Sheet_1.pdf. 2020,		
46	Image_1.TIF. 2020,		
45	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. 2021, 13, 163		2
44	IDENTIFY THE CURRENT TRENDS RELATED TO THE TREATMENT AND PREVENTION OF COVID- 19. 2022, 1, 17-21		
43	Risk Factors and Outcome of Sepsis in Traumatic Patients and Pathogen Detection Using Metagenomic Next-Generation Sequencing.. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 2549413	2.6	
42	Recent evidence-based treatments for COVID-19: A Review. <i>Anti-Infective Agents</i> , 2022, 20,	0.6	
41	Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.. <i>PLoS ONE</i> , 2022, 17, e0267645	2.7	0
40	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <i>Anti-Infective Agents</i> , 2022, 20,	0.6	
39	Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. <i>World Journal of Experimental Medicine</i> , 2022, 12, 44-52	0.4	0
38	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022, 15, 634	5.2	1
37	Efficacy of COVID-19 treatments among geriatric patients: a systematic review. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210956	2.8	0
36	The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , 2022,	4.4	0
35	Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
34	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , Volume 18, 603-617	2.9	0
33	COVID-19 tanşıyla evde takip edilen hastaların hidroksiklorokin tedavisine uyumları ve geri bildirimleri. <i>Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi</i> ,		
32	Enterprise Profitability and Financial Evaluation Model Based on Statistical Modeling: Taking Tencent Music as an Example. <i>Mathematics</i> , 2022, 10, 2107	2.3	0
31	COVID-19 pandemic in the Arctic and Subarctic. 2022, 143-156		

30	Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). <i>Journal of Heterocyclic Chemistry</i> , 1.9	o
29	Synergistic Action of AMX Associated with 1,8-Cineole and Its Effect on the ESBL Enzymatic Resistance Mechanism. <i>Antibiotics</i> , <b>2022</b> , 11, 1002	4.9 o
28	Knowledge and compliance of hydroxychloroquine prophylaxis for severe acute respiratory syndrome coronavirus 2 infection among Indian health-care workers. <b>2022</b> , 11, 33	
27	Analysis of hydroxychloroquine adverse events in COVID-19 patients reported throughout Iraqi pharmacovigilance center in VigiBase—A study based on WHO database. 11, 923	
26	Humoral and cellular response in convalescent COVID-19 lupus patients. <b>2022</b> , 12,	
25	SMILES generation against Covid-19 with Encoder-Decoder LSTM and PCA's features.	
24	Role of transforming growth factor-beta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung Injury: a prospective, observational, cohort study. 55,	1
23	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.	o
22	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
21	Effect of synbiotics on inflammatory markers and white blood cell count in COVID-19 patients: a randomized, double-blind, placebo-controlled clinical trial.	o
20	Citation Misuses in the Biomedical Literature and Its Effects on Public Health. <b>2022</b> , 417-426	o
19	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12	o
18	Pathogen Detection in Ornithodoros sonrai Ticks and Invasive House Mice Mus musculus domesticus in Senegal. <b>2022</b> , 10, 2367	o
17	Changes in drug demand when a pandemic coincides with other outbreaks in a war zone country: a cross-sectional pilot study. <b>2022</b> , 15,	1
16	Small molecules in the treatment of COVID-19. <b>2022</b> , 7,	3
15	Serum calprotectin can indicate current and future severity of COVID -19.	o
14	G6PD Deficiency and COVID-19 in Burkina Faso: A Possible Link?. <b>2023</b> , 11, 57-69	o
13	Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.	o

- 12 COVID-19: Ophthalmology Perspective. **2023**, 417-427 ○
- 11 Correlation between Medications Used during COVID Infection and Post-conditions after the Acute Phase of Infection: A Cross-sectional Study. **2022**, 15, ○
- 10 Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. **2023**, 99-139 ○
- 9 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, ○
- 8 Comprehensive micropollutant characterization of wastewater during Covid-19 crisis in 2020: Suspect screening and environmental risk prioritization strategy. **2023**, 873, 162281 ○
- 7 Are we ready to combat the ecotoxicity of COVID-19 pharmaceuticals? An in silico aquatic risk assessment. **2023**, 256, 106416 ○
- 6 COVID -19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats. **2023**, 11, ○
- 5 Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. **2023**, 59, 541 ○
- 4 The main treatments used for SARS-CoV-2 patients. **2022**, 3, 095-103 ○
- 3 Antibiotic Usage in the COVID-19 Intensive Care Unit of an Infectious Diseases Hospital from Nord-Eastern Romania. **2023**, 59, 645 ○
- 2 A comment-driven evidence appraisal approach to promoting research findings into practice when only uncertain evidence is available. **2023**, 21, ○
- 1 Bibliographie. **2023**, 137-181 ○